Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 7.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

The stock's fall snapped a four-day winning streak.

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Read on to discover why many could benefit from investing in this terrific company. On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment ...